Newsfeeds - Spark Newswire

1 minute read

Avidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trial

Today, 6:31 PM

Avidity Biosciences Inc (NASDAQ:RNA) announced AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever…

RNA

1 minute read

Avidity Announces AOC 1001 Phase 1/2 MARINA Data Demonstrating Successful Targeted Delivery Of RNA to Muscle

By Bill Haddad

Today, 6:31 PM

AOC 1001 delivered siRNA to skeletal muscle and produced meaningful DMPK reduction in 100% of participants with a 45% mean reduction in DMPK after a single dose of 1 mg/kg or two doses of 2 mg/kg AOC

RNA

13 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 6:31 PM

Wednesday saw 219 companies set new 52-week lows.

$APE

11 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 6:31 PM

Tuesday's session saw 167 companies set new 52-week lows.

ACHL

3 minute read

Avidity Biosciences Announces Phase 1/2 EXPLORE44 Trial Of AOC 1044 For Duchenne Muscular Dystrophy Mutations Amenable To Exon 44 Skipping

By Benzinga Newsdesk

Today, 6:31 PM

AOC 1044 is the first antibody oligonucleotide conjugate (AOC™) of multiple Duchenne muscular dystrophy programs to enter the clinic First AOC from Avidity's RNA platform technology engineered to deliver

RNA